PT-141
Also known as: Bremelanotide, Vyleesi, Melanocyte-Stimulating Hormone
The first FDA-approved peptide for sexual dysfunction — centrally acting with proven clinical results.
Sexual Health
PT-141
FDA-approved (Vyleesi) for women with HSDD. Requires prescription. May cause nausea, flushing, and transient blood pressure increases.
Overview
PT-141 (Bremelanotide) is a synthetic melanocortin peptide and the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women (brand name Vyleesi). Unlike PDE5 inhibitors (sildenafil/tadalafil) which work through vascular mechanisms, PT-141 acts centrally through melanocortin receptors in the brain to enhance sexual desire and arousal in both women and men.
PT-141 (Bremelanotide) is a synthetic cyclic peptide derived from Melanotan II, which was itself a structural analog of the naturally occurring melanocyte-stimulating hormone (α-MSH). During early research into Melanotan II as a potential tanning agent, investigators observed unexpected sexual arousal effects — which led to targeted development of PT-141 as a selective melanocortin agonist for sexual dysfunction. This serendipitous discovery pathway ultimately produced the first FDA-approved drug for hypoactive sexual desire disorder (HSDD) in premenopausal women, branded as Vyleesi.
The mechanism that distinguishes PT-141 from all other approved treatments for sexual dysfunction is its central nervous system activity. Phosphodiesterase-5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis) work peripherally — they enhance nitric oxide-mediated vasodilation in genital tissue, improving blood flow to facilitate the physical mechanics of arousal. PT-141 operates upstream of this process by activating melanocortin MC3R and MC4R receptors in the hypothalamus and limbic system — brain regions involved in sexual motivation, desire, and emotional processing. This central mechanism means PT-141 can address desire and motivation rather than just physical response, and it works independently of vascular function, making it effective in populations where PDE5 inhibitors have limited utility.
The FDA approval process for PT-141 as Vyleesi (approved 2019 at 1.75 mg for premenopausal women with HSDD) involved multiple Phase III clinical trials that demonstrated statistically significant improvements in desire and reductions in distress related to low sexual desire — the two primary endpoints required for HSDD approval. The approval established a regulatory record confirming safety and efficacy in human subjects at doses consistent with those used in off-label applications. Common side effects from the trials included nausea (approximately 40% of participants), flushing, and transient increases in blood pressure — effects that are dose-dependent and manageable with appropriate titration.
Off-label use encompasses both men and women with sexual dysfunction of psychological or neurological origin — cases where inadequate desire (rather than inadequate vascular response) is the primary issue. This distinction is clinically important: TRT patients who restore testosterone levels but find libido still impaired, individuals with medication-induced sexual dysfunction (particularly SSRIs), and patients with neurological conditions affecting sexual motivation represent populations where PT-141's central mechanism addresses a need that peripherally-acting drugs cannot.
Mechanism of Action
PT-141 is an agonist of melanocortin receptors (MC3R and MC4R) in the hypothalamus and limbic system. This central mechanism directly increases sexual desire and arousal pathways, rather than working through vascular or hormonal changes.
Use Cases
- ✓Hypoactive sexual desire disorder (FDA-approved for women)
- ✓Female sexual arousal disorder
- ✓Male erectile dysfunction and libido (off-label)
- ✓Sexual dysfunction in both sexes
Research Summary
FDA approval was based on RECONNECT trials demonstrating significantly increased satisfying sexual events and reduced distress in women with HSDD. Off-label male studies show improved erectile function and libido, particularly effective when PDE5 inhibitors have failed.
Explain It Like I'm 5 Years Old
There are two ways to feel like being close to someone special — one is about how your body physically works, and another is about whether your brain actually wants to. PT-141 works on the second one — it goes to the part of your brain that creates the desire and feeling of wanting to connect, and turns it up. Actual doctors approved it as a real medicine because it works this way.
How the Gym Bros Are Using It
The "desire peptide" — and it genuinely works differently from Cialis or Viagra. Those drugs help with blood flow. PT-141 works in your brain's limbic system to increase the actual want-to, not just the ability. Inject 1–1.75 mg subcutaneously about 60–90 min before. FDA-approved at 1.75 mg for women — gym bros use it off-label at 1–2 mg. The nausea at higher doses is the main complaint, so start at 1 mg to test tolerance. Very popular among TRT users who find testosterone improved their performance but didn't fully restore libido. Effect lasts several hours.
Typical Dosing
FDA-approved: 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity (max 1x per 24 hours, 8x per month). Off-label male dose: 1–2 mg.
Administration
Prescription Only
FDA-approved (Vyleesi) for women with HSDD. Requires prescription. May cause nausea, flushing, and transient blood pressure increases.
